# A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

> **NCT00743275** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 120 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)

## Key facts

- **NCT ID:** NCT00743275
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2016-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743275, "A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00743275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*